Qisda Corp., a leading IT company with business in medical care, has launched a new vision of "more than half of the profits from its high value-added business by 2027" this year, with the medical business at its centre. Among them, retail has made new progress by expanding its investment, and BenQ Medical Centres have officially launched its stock listing plan.  

Qisda's Chairman, Mr Peter Chen, said that the two Medical Centres (Suzhou and Nanjing) have continued to grow in revenue since the end of the epidemic, surpassing $10 billion for the first time last year, and making strong profits.

In addition to the ongoing expansion of hospitals in Nanjing in Suzhou, including the completion of the medical research and development centre at Suzhou's facility in the second quarter of this year, the second phase of construction at Nanjing BenQ Medical Centre is expected to be completed and opened in the third quarter of next year. The Group is also continuing to expand its presence in other local hospitals. The company expects the rapid growth of medical business to bring higher value to the Qisda Group in the future.

As to the timing of the listing of BenQ Medical Centre, Mr Chen said that it might take some time. In fact, the operation and profitability of the Centre has already met all the listing criteria. Preparation for listing is currently in progress.

The Qisda Group's medical business development strategy focuses on "channel first". Following the accelerated growth of BenQ Medical Centre's operations, Qisda has recently expanded its medical business to include pharmacy channels, and has expanded its strategic partnership to include a pharmacy group with chain stores in Taiwan. 

According to Chen, the Group has decided to expand its investment in pharmacies to build up the pharmaceuticals channel, just as it did when it first established the medical channel (BenQ Medical Centre), and will not rule out entering the pharmaceuticals sector whenever good opportunities are there.